# Aflibercept Treat-and-Extend Protocol with 8-week Minimum (Full Version)
# For comparing with fixed T&T protocol - all fields included

name: "Aflibercept T&E (8-week minimum)"
version: "1.0"
created_date: "2025-01-24"
author: "Calibration Team"
description: "Treat-and-extend protocol with NHS-compliant 8-week minimum interval"

# Protocol type - treat and extend
protocol_type: "treat_and_extend"

# T&E intervals - NHS constraint of 8-week minimum
min_interval_days: 56      # 8 weeks (NHS minimum)
max_interval_days: 112     # 16 weeks maximum
extension_days: 14         # Extend by 2 weeks if stable
shortening_days: 14        # Shorten by 2 weeks if active

# Disease state transitions - shared with T&T for fair comparison
disease_transitions:
  NAIVE:
    NAIVE: 0.0
    STABLE: 0.45      # 45% achieve stability after loading
    ACTIVE: 0.45      # 45% remain active
    HIGHLY_ACTIVE: 0.10
  STABLE:
    NAIVE: 0.0
    STABLE: 0.88      # High retention when stable
    ACTIVE: 0.12      # Some recurrence
    HIGHLY_ACTIVE: 0.0
  ACTIVE:
    NAIVE: 0.0
    STABLE: 0.35      # Can improve with treatment
    ACTIVE: 0.55      # Many remain active
    HIGHLY_ACTIVE: 0.10
  HIGHLY_ACTIVE:
    NAIVE: 0.0
    STABLE: 0.10
    ACTIVE: 0.30
    HIGHLY_ACTIVE: 0.60

# Treatment effect on disease transitions
treatment_effect_on_transitions:
  NAIVE:
    multipliers: {}
  STABLE:
    multipliers:
      STABLE: 1.2      # 20% more likely to stay stable
      ACTIVE: 0.8      # 20% less likely to become active
  ACTIVE:
    multipliers:
      STABLE: 2.5      # 2.5x more likely to become stable
      ACTIVE: 0.7      # 30% less likely to stay active
      HIGHLY_ACTIVE: 0.5  # 50% less likely to worsen
  HIGHLY_ACTIVE:
    multipliers:
      STABLE: 2.0      # Twice as likely to improve dramatically
      ACTIVE: 1.8      # 80% more likely to improve
      HIGHLY_ACTIVE: 0.6  # 40% less likely to remain severe

# Vision change model - shared with T&T
vision_change_model:
  naive_treated:
    mean: 3.0
    std: 2.0
  naive_untreated:
    mean: -3.0
    std: 2.0
  stable_treated:
    mean: 1.5
    std: 1.5
  stable_untreated:
    mean: -0.5
    std: 1.0
  active_treated:
    mean: 0.5
    std: 2.0
  active_untreated:
    mean: -3.0
    std: 2.0
  highly_active_treated:
    mean: -0.5
    std: 2.0
  highly_active_untreated:
    mean: -5.0
    std: 3.0

# Baseline vision distribution
baseline_vision_distribution:
  type: normal
  mean: 55
  std: 15
  min: 20
  max: 85

# Discontinuation rules
discontinuation_rules:
  poor_vision_threshold: 35
  poor_vision_probability: 0.05
  high_injection_count: 25
  high_injection_probability: 0.02
  long_treatment_months: 60
  long_treatment_probability: 0.02
  discontinuation_types: ['planned', 'adverse', 'ineffective']

# Clinical improvements - T&E specific response distribution
clinical_improvements:
  enabled: true
  use_loading_phase: true
  use_time_based_discontinuation: true
  use_response_based_vision: true
  use_baseline_distribution: false
  use_response_heterogeneity: true
  
  # T&E-specific: 60% optimal responders (from cost calculator)
  response_types:
    good:
      probability: 0.60    # 60% optimal responders who can extend
      multiplier: 1.8      # Better vision gains
    average:
      probability: 0.30    # 30% moderate responders
      multiplier: 1.0      # Normal vision gains
    poor:
      probability: 0.10    # 10% poor responders
      multiplier: 0.5      # Reduced vision gains
  
  # Discontinuation probabilities
  discontinuation_probabilities:
    1: 0.10   # 10% Year 1
    2: 0.15   # 15% Year 2 
    3: 0.12   # 12% Year 3
    4: 0.08   # 8% Year 4
    5: 0.075  # 7.5% Year 5+
  
  # Vision response parameters
  vision_response_params:
    loading:
      mean: 4.0
      std: 1.5
    year1:
      mean: 1.0
      std: 1.0
    year2:
      mean: 0.0
      std: 1.0
    year3plus:
      mean: -0.3
      std: 1.0

# Target outcomes for validation
target_outcomes:
  year1:
    mean_bcva_change: 6.0    # 5-6 letters expected
    mean_injections: 7.5     # 7-8 injections
  year2:
    mean_bcva_change: 5.0    # Slight decline from peak
    cumulative_injections: 12.5  # ~5 in year 2